» Articles » PMID: 23311768

Effects of 12 Months of Treatment with Disease-modifying Anti-rheumatic Drugs on Low and High Density Lipoprotein Subclass Distribution in Patients with Early Rheumatoid Arthritis: a Pilot Study

Overview
Publisher Informa Healthcare
Specialty Rheumatology
Date 2013 Jan 15
PMID 23311768
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Patients with rheumatoid arthritis (RA) have increased cardiovascular risk. The aim of the present study was the assessment of low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass distribution in patients with early RA (ERA, n = 30) compared with age- and sex-matched healthy subjects (n = 30), as well the effect of treatment for 12 months with the disease-modifying anti-rheumatic drugs (DMARDs) methotrexate and prednisone in this distribution.

Method: LDL and HDL subclass distribution was determined using a polyacrylamide gel-tube electrophoresis method.

Results: ERA patients exhibited increased levels of inflammatory markers and high disease activity score. ERA patients had higher serum levels of total cholesterol (TC), LDL cholesterol (LDL-C), and triglycerides (TG) whereas their serum HDL cholesterol (HDL-C) levels were significantly lower compared with controls. ERA patients exhibited significantly higher plasma levels of small dense LDL-C (sdLDL-C), leading to a significantly decreased mean LDL diameter. ERA patients had significantly decreased small HDL particles (HDL-3) concentration whereas serum levels of large HDL particles (HDL-2) did not differ compared with controls. Treatment with DMARDs resulted in a significant decrease in inflammatory markers and disease activity, along with a significant increase in HDL-C serum levels. The concentration of sdLDL-C did not change significantly during treatment. We observed a significant increase in the levels of large HDL-2 whereas the concentration of small HDL-3 did not significantly change.

Conclusions: Patients with ERA have increased sdLDL-C levels and decreased HDL-C levels because of decreased concentration of the small HDL-3 subclass. The administration of DMARDs induced a significant increase in HDL-C levels, which was attributed to the increase in large HDL-2 serum concentration.

Citing Articles

The Composition of the HDL Particle and Its Capacity to Remove Cellular Cholesterol Are Associated with a Reduced Risk of Developing Active Inflammatory Rheumatoid Arthritis.

Giacaglia M, Felix V, Santana M, Amendola L, Lerner P, Fernandes S Int J Mol Sci. 2024; 25(20).

PMID: 39456762 PMC: 11507075. DOI: 10.3390/ijms252010980.


Nrf2-mediated ferroptosis inhibition: a novel approach for managing inflammatory diseases.

Han H, Zhang G, Zhang X, Zhao Q Inflammopharmacology. 2024; 32(5):2961-2986.

PMID: 39126567 DOI: 10.1007/s10787-024-01519-7.


Dyslipidemia in rheumatoid arthritis: the possible mechanisms.

Yan J, Yang S, Han L, Ba X, Shen P, Lin W Front Immunol. 2023; 14:1254753.

PMID: 37954591 PMC: 10634280. DOI: 10.3389/fimmu.2023.1254753.


-Acetylcysteine overcomes epalrestat-mediated increase of toxic 4-hydroxy-2-nonenal and potentiates the anti-arthritic effect of epalrestat in AIA model.

Wang L, Huang B, Zeng Y, Yang J, Li Z, Ng J Int J Biol Sci. 2023; 19(13):4082-4102.

PMID: 37705749 PMC: 10496504. DOI: 10.7150/ijbs.85028.


The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study.

Papamichail G, Markatseli T, Georgiadis A, Xydis V, Milionis H, Drosos A Heart Vessels. 2022; 37(12):2128-2136.

PMID: 35739432 DOI: 10.1007/s00380-022-02114-y.